STEDIRIL (ethinylestradiol 50 μg, norgestrel 500 μg), hormonal contraceptive

CONTRACEPTION - Update

Opinions on drugs - Posted on Jun 24 2015

Renewal of inclusion and re-assessment of the actual benefit

STEDIRIL has Marketing Authorisation in oral hormonal contraception.Its risk of venous and arterial thromboembolism is greater than that of other 2nd generation combined oral contraceptives containing less ethinylestradiol.
It has no role in the contraceptive strategy because of the existence of 1st and 2nd generation combined oral contraceptives containing less ethinylestradiol. It therefore does not have sufficient actual benefit to justify its reimbursement.

Insufficient

Therapeutic use

Évaluation des médicaments

All our publications

My account